MedWire News: Daily lasofoxifene 0.5 mg reduces the risk for major coronary heart disease (CHD) events and stroke in postmenopausal women with osteoporosis, but increases the incidence of venous thromboembolic events (VTEs), a substudy of the PEARL trial shows.
